The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | CONCORDE: novel agents with radiotherapy in non-small cell lung cancer
Alastair Greystoke, PhD, MBChB, MRCP, Newcastle University, Newcastle, UK, discusses the CONCORDE study (NCT04550104), which investigates the addition of new drugs to radical dose radiotherapy in patients with stage II or III non-small cell lung cancer (NSCLC) who are not suitable for concurrent chemoradiotherapy. The study has registered almost 150 patients and randomized over 100 patients, with preliminary efficacy data to be presented for some of the arms that are still recruiting. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So today at BTOG I’ll be presenting at the academic landscape session on the Concorde study. This is a platform study we’ve been running for the last seven years in the United Kingdom, England, Scotland and Wales. It’s funded by Cancer Research UK and AstraZeneca. It’s a very novel study. It’s looking at adding in new drugs to radical dose radiotherapy in patients with stage two or stage three non-small cell lung cancer who are not suitable for concurrent chemoradiotherapy...
So today at BTOG I’ll be presenting at the academic landscape session on the Concorde study. This is a platform study we’ve been running for the last seven years in the United Kingdom, England, Scotland and Wales. It’s funded by Cancer Research UK and AstraZeneca. It’s a very novel study. It’s looking at adding in new drugs to radical dose radiotherapy in patients with stage two or stage three non-small cell lung cancer who are not suitable for concurrent chemoradiotherapy. So this is a less fit population. You can’t receive the gold standard treatment. What we’ve done over the last seven years is set up a platform where we’ve run four arms where we’ve added in DNA damage repair inhibitors, tablet therapies, and in selected patients, we’ve also given them immunotherapy with durvalumab. I’m going to be updating the community on our progress to date over the last seven years. We’ve registered almost 150 patients. We’ve randomized over 100 patients. One arm, unfortunately, has been closed for safety, but I’m also going to show some very preliminary efficacy data for some of the arms that are still recruiting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
